NO881077L - Kjemo-radio-immuno-konjugater. - Google Patents

Kjemo-radio-immuno-konjugater.

Info

Publication number
NO881077L
NO881077L NO881077A NO881077A NO881077L NO 881077 L NO881077 L NO 881077L NO 881077 A NO881077 A NO 881077A NO 881077 A NO881077 A NO 881077A NO 881077 L NO881077 L NO 881077L
Authority
NO
Norway
Prior art keywords
conjugate
antibody
agent
radionuclide
group
Prior art date
Application number
NO881077A
Other languages
English (en)
Norwegian (no)
Other versions
NO881077D0 (no
Inventor
Joseph A Sinkule
Donald J Buchsbaum
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of NO881077D0 publication Critical patent/NO881077D0/no
Publication of NO881077L publication Critical patent/NO881077L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO881077A 1987-03-11 1988-03-10 Kjemo-radio-immuno-konjugater. NO881077L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3070087A 1987-03-11 1987-03-11

Publications (2)

Publication Number Publication Date
NO881077D0 NO881077D0 (no) 1988-03-10
NO881077L true NO881077L (no) 1988-09-12

Family

ID=21855550

Family Applications (1)

Application Number Title Priority Date Filing Date
NO881077A NO881077L (no) 1987-03-11 1988-03-10 Kjemo-radio-immuno-konjugater.

Country Status (6)

Country Link
EP (1) EP0282057A3 (de)
JP (1) JPS63301833A (de)
CN (1) CN88102026A (de)
AU (1) AU1301788A (de)
DK (1) DK134288A (de)
NO (1) NO881077L (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337598A3 (de) * 1988-02-26 1991-07-03 Georgia State University Foundation, Inc. Verwendung von Porphyrinen und Metalloporphyrinen zur Behandlung von durch HIV verursachten Krankheiten
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
AU629367B2 (en) * 1989-06-19 1992-10-01 Akzo N.V. Radioimmunotherapy using alpha-particles emission
US5030450A (en) * 1989-11-28 1991-07-09 Abbott Laboratories Method for inhibiting nematode infection of plants with Nematostatic trichothecene compositions
WO1991013633A1 (en) * 1990-03-12 1991-09-19 Cancer Research Campaign Technology Limited Improvements relating to immunoradiotherapy
DE19514088A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen
EP0855910A4 (de) * 1995-10-18 2000-07-05 Merck & Co Inc Verwendbare konjugate zur behandlung der gutartigen prostatehyperplasie
WO1998009651A1 (en) * 1996-09-03 1998-03-12 Chugai Seiyaku Kabushiki Kaisha ANTI-INTEGRIN α3 ANTIBODY COMPLEXES
JP5064608B2 (ja) * 1998-05-26 2012-10-31 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ アルファ粒子放出構成物およびその使用方法
US7736651B1 (en) 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
CN1110322C (zh) * 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2003007889A2 (en) 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
DE102004016355A1 (de) * 2004-04-02 2005-11-03 Rösner Research GmbH & Co.KG Herstellung und Verwendung des Konjugats Methotrexat-Albumin als Mittel zur Immunosuppression bei GVHD
DE102004057196A1 (de) * 2004-11-26 2006-06-01 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Konjugaten mit Nicht-steroidalen Antirheumatika (NSAR)
WO2008043148A1 (en) * 2006-10-11 2008-04-17 Medvet Science Pty. Ltd. The use of a dna damaging agent and a ligand for the treatment of cancer
CN108226531A (zh) * 2017-12-27 2018-06-29 三诺生物传感股份有限公司 一种β2-微球蛋白检测试剂盒
AU2021390552A1 (en) * 2020-12-04 2023-06-29 The Regents Of The University Of California Peptide receptor radionuclide therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates

Also Published As

Publication number Publication date
DK134288A (da) 1988-09-12
CN88102026A (zh) 1988-09-28
JPS63301833A (ja) 1988-12-08
EP0282057A3 (de) 1990-03-07
EP0282057A2 (de) 1988-09-14
AU1301788A (en) 1988-09-15
DK134288D0 (da) 1988-03-11
NO881077D0 (no) 1988-03-10

Similar Documents

Publication Publication Date Title
NO881077L (no) Kjemo-radio-immuno-konjugater.
EP0732939B1 (de) Herstellung und Verwendung von Immunkonjugaten die eine VL-Kette enthalten welche am Asn in Position 18 glykosyliert ist
US5194594A (en) Modified antibodies
US5990286A (en) Antibodies with reduced net positive charge
EP0251494A2 (de) Therapeutische oder radiodiagnostische Substanz
JPS6270377A (ja) ハプテンで修飾された診断薬および治療薬の抗体コンプレツクス
JPH0762032B2 (ja) 改良された放射性核種抗体カツプリング
US6576746B2 (en) Site-specific labeling of disulfide-containing targeting vectors
Casey et al. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab'fragments
JP2012131808A (ja) 減少した正味の正電荷を有する抗体
Hudecz et al. Immunoconjugate design: a predictive approach for coupling of daunomycin to monoclonal antibodies
US20030235534A1 (en) Methods and compositions for radioimmunotherapy of brain and CNS tumors
Lindegren et al. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy
Hawkins et al. Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system
US5380513A (en) Methods for reducing non-target retention of immunoconjugates and metabolites thereof
WO1987004164A1 (en) Technetium-antibody conjugate
Foxwell et al. Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P
JP4680387B2 (ja) ジスルフィド含有標的ベクターの部位特異的標識化
AU687145C (en) Preparation and use of immunoconjugates
Wu Novel bifunctional linkers for antibody chelation with radiometals
Frey Preparation, characterization and biological evaluation of cellobiose and dextran carriers of prosthetically labeled iodine-125 for use in radioimmunotherapy of tumors of glial origin
AU6843287A (en) Technetium-antibody conjugate
Wu 11. Novel bifunctional linkers for antibody chelation